Antipsychotic adherence is one of the hardest measures in medicine. It is also one of the most heavily weighted.
Health plans track antipsychotic adherence and psychiatric readmissions on the panel tied to your practice. When a patient stops their antipsychotic, the HEDIS score falls and the value based contracts tied to your practice are affected. Fairview Pharmacy holds an EQuIPP star rating of 5.00 from Elevate Provider Network, Quarter 4, 2025, and we help your patients stay on therapy.
What happens between visits
Staying on an antipsychotic is hard. Most of the reasons are solvable.
Antipsychotic non-adherence is one of the most persistent challenges in psychiatry. Side effects drive patients to stop. Long acting injectable due dates get missed. A confusing or public pharmacy experience drives patients away. Cost and prior authorizations interrupt therapy. Each of those is a solvable pharmacy problem, and a chain pharmacy solves none of them. The relapse and the readmission that follow are invisible to you until a crisis call or a discharge summary.
Psychiatry specific quality risk
Antipsychotic adherence is a core tracked measure.
HEDIS SAA, antipsychotic adherence in schizophrenia
The share of your schizophrenia patients who maintain at least 80 percent adherence to their antipsychotic. When a patient stops therapy, this score falls for every plan that patient belongs to.
Psychiatric readmissions
A patient who stops their antipsychotic is at higher risk of relapse, and a psychiatric readmission lands on the measure tied to your panel and your value based contracts.
Follow Up After Hospitalization (FUH) and MIPS quality
Follow Up After Hospitalization for Mental Illness, and overall MIPS quality. Patients who never stabilize on therapy are associated with lower scores on both. MIPS adjustments can reach up to 9 percent, a maximum.
Antipsychotic adherence is one of the hardest measures to move. A pharmacy that actively tracks injections and supports adherence is a direct help to your scores.
The liability between you and your HEDIS scores
At a chain pharmacy, the long acting injectable due date is nobody's job to track.
If a patient's injection is due, nobody tracks it. If side effects scare them off, nobody calls. If they stop, nobody tells you. And a loud, public pharmacy counter with no privacy is, for many patients, a reason to avoid the pharmacy altogether. You learn months later, from a crisis call or a hospital discharge.
That is not a pharmacy partner. That is a liability sitting between you and the HEDIS scores tied to your practice.
EQuIPP verified, all four measures published
Fairview tracks every injection and supports every patient privately.
EQuIPP star measures, Elevate Provider Network. Quarter 4, 2025, closed measurement year.
- Blood pressure (RASA) PDC98.2%, 215 of 219 patients5 stars
- Cholesterol PDC97.2%, 246 of 253 patients5 stars
- Statin use in diabetes96.3%, 52 of 54 patients5 stars
- Diabetes PDC95.6%, 108 of 113 patients5 stars
EQuIPP star rating 5.00. Five stars on all four measures, every year since 2022.
Fairview's EQuIPP star measure performance, issued by Elevate Provider Network for the closed 2025 measurement year: Blood pressure (RASA) PDC 98.2%, 215 of 219 patients. Cholesterol PDC 97.2%, 246 of 253. Statin use in diabetes 96.3%, 52 of 54. Diabetes PDC 95.6%, 108 of 113. EQuIPP star rating 5.00. Five stars on all four measures, every year since 2022. The same refill tracking, outreach, and prior authorization systems that produce those numbers are exactly what we apply to every antipsychotic we dispense, in a private, consistent, respectful setting.
EQuIPP performance metrics as of Quarter 4, 2025, Medicare Part D population, benchmarked against national pharmacy averages. These measures describe prescribing and dispensing patterns. Neither is a measure of health outcomes.
You prescribe.
E prescribe to Fairview. NCPDP 2515104, NPI 1144383613.
We fill same day.
We clear every prior authorization.
We track injections.
We track every long acting injectable due date and call patients before refills lapse.
We report to you.
A one page adherence report at day ninety on the patients you referred.
You reinforce.
You address adherence at the next visit.
Same day fills
Every antipsychotic and long acting injectable prescription filled within 24 hours.
100% prior authorization handling
We carry the full antipsychotic and injectable prior authorization burden for your staff.
Injection schedule tracking
We track every long acting injectable due date and flag a missed dose.
A one page report at day ninety
Who is on track and who is not, delivered at day ninety.
Private consultation
A discreet space and one consistent pharmacist, not a loud counter.
Proactive refill calls
We reach patients before the gap forms.
Start with 5, zero risk
Send us 5 of your most complex patients. 90 days. Zero risk.
We resolve the prior authorizations, track every injection, support adherence, and report to your office at day ninety. No contract, no cost, and nothing owed in either direction. If the reports are not useful, tell us and we will change the format.
Request your intro call
A 10 minute call with Dr. Mike, no commitment and no paperwork to start. Just tell us how to reach you and a little about your practice. The 5 patient pilot is what we walk through on the call.
Typical response: Within 1 business day
Forms for referring practices
Prefer paper? Download, complete, and fax to 601 583 2298.
Coordinating a long acting injectable? Download the injectable coordination form above and fax it with the referral. We deliver the injectable to your clinic, timed to the appointment.